Urinary Tract Infection in Cancer Patients at Government Cancer Hospital Aurangabad, India

Khaparkuntikar, Mukta; Siddiqui, Nazneen; Bhirud, Prasanna

doi:10.20546/ijcmas.2017.605.251

Cited by 5 publications

(7 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of a more important note, there are high resistance rates to fluroquinolones and third generation cephalosporins in the “Watch” group and some were resistant to antibiotics in the “Reserve” group. This finding was in line with other studies [ 19 , 20 , 31 ]. This points to the need for optimal and rational use of antibiotics in cancer patients to prevent antibiotic resistance, as well as improvement of quality of antibiotic resistance testing.…”

Section: Discussionsupporting

confidence: 94%

“…Urinary tract infection (UTI) is one of the most common infections among cancer patients due to their prolonged immunosuppression, complex cancer treatment and catherization [ 18 , 19 ]. Treating UTI in cancer patients is clinically challenging as many cancer patients are at high risk of AMR due to long-term chemotherapies, depressed immune systems and repeated use of antibiotics to prevent and/or treat infections [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bacterial Profile and Antibiotic Resistance among Cancer Patients with Urinary Tract Infection in a National Tertiary Cancer Hospital of Nepal

et al. 2021

View full text Add to dashboard Cite

Cancer patients are at high risk of antibiotic resistant bacterial urinary tract infections (UTIs). In this study, we assessed the bacterial profile and antibiotic resistance among cancer patients suspected of UTI in B.P. Koirala Memorial Cancer Hospital in Nepal through a cross-sectional study with routinely collected data. All cancer patients who had a recorded urine culture between July 2018–June 2019 were included in the study. Out of 308 patients who had undergone culture, 73 (24%) of samples had bacterial growth. The most common organisms isolated were E. coli (58%), Staphylococcus (11%) and Klebsiella (10%). These bacteria had undergone susceptibility testing to 27 different antibiotics in various proportions. Of the limited antibiotic testing levels, nitrofurantoin (54/66, 82%) and amikacin (30/51, 59%) were the most common. Among those tested, there were high levels of resistance to antibiotics in the “Access” and “Watch” groups of antibiotics (2019 WHO classification). In the “Reserve” group, both antibiotics showed resistance (polymyxin 15%, tigecycline 8%). Multidrug resistance was seen among 89% of the positive culture samples. This calls for urgent measures to optimize the use of antibiotics in UTI care at policy and health facility levels through stewardship to prevent further augmentation of antibiotic resistance among cancer patients.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Bacterial Profile and Antibiotic Resistance among Cancer Patients with Urinary Tract Infection in a National Tertiary Cancer Hospital of Nepal

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This study revealed that the main isolated organisms from urine culture taken from cancer patients were Escherichia coli (72.4%). This is comparable with previous studies reported by Bhusa et al [12] in the USA, Tancheva et al [9] in Varna, Mukta et al [13] in India, and Chandra et al [14] in India but with lower rates than our study, where the rates were 69.5%, 64.7%, 38.09%, 37.5%, respectively.…”

Section: Discussionsupporting

confidence: 92%

“…The resistance to imipenem seen in our study, which is more than any other previous study, perhaps finds a logical explanation due to the frequent use of imipenem as routine treatment for resistant strains. Other studies reported lower rates of resistance to imipenem, such as Sedighi et al [15] in Iran, who reported it to be 3.3% and Mukta et al [13] in Bulgaria, who found the resistance to be 9%. In addition, Elsayed et al [16], in Egypt, reported that the resistance rate was 2%.…”

Section: Discussionmentioning

confidence: 90%

Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic E. coli Isolated from Cancer Patients

et al. 2020

View full text Add to dashboard Cite

Cancer patients are more susceptible to several bacterial infections, particularly urinary tract infections caused by uropathogenic E. coli (UPEC). The objective of this work was detection and the phylogenetic characterization of hospital-acquired isolates of uropathogenic E. coli in cancer patients and the determination of its relation with antibiotic resistance. A total of 110 uropathogenic E. coli responsible for hospital-acquired urinary tract infections in cancer patients were included in this study. A triplex PCR was employed to segregate different isolates into four different phylogenetic groups (A, B1, B2 and D). Drug resistance was evaluated by the disc diffusion method. All of the isolates were multiple drug-resistant (MDR) and 38.18% of all UPEC isolates were extended-spectrum beta-lactamase (ESBL) producers from which 52% were positive for the blaCTX-M gene, 40% for the blaTEM gene, and 17% for the blaSHVgene. Among 42 ESBL-producing uropathogenic E. coli isolates, the majority belonged to phylogenetic group B2 (43%), followed by group D (36%), group A (19%) and group B1 (2%). Our results have shown the emergence of MDR isolates among uropathogenic E. coli with the dominance of phylogenetic group B2. Groups A and B1 were relatively less common. The most effective drug in all phylogenetic groups was imipenem.

show abstract

“…Multidrug resistance is frequent in cancer patients with UTIs (96%) [188]. A high proportion of resistance to fluroquinolones (90-96%), cephalosporins (68-80%), and aminoglycosides (46-50%) has been observed [189,190].…”

Section: Urinary Tract Infectionsmentioning

confidence: 99%

Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors

Kubeček

Paterová

Novosadová

2021

Life

View full text Add to dashboard Cite

Infections represent a significant cause of morbidity and mortality in cancer patients. Multiple factors related to the patient, tumor, and cancer therapy can affect the risk of infection in patients with solid tumors. A thorough understanding of such factors can aid in the identification of patients with substantial risk of infection, allowing medical practitioners to tailor therapy and apply prophylactic measures to avoid serious complications. The use of novel treatment modalities, including targeted therapy and immunotherapy, brings diagnostic and therapeutic challenges into the management of infections in cancer patients. A growing body of evidence suggests that antibiotic therapy can modulate both toxicity and antitumor response induced by chemotherapy, radiotherapy, and especially immunotherapy. This article provides a comprehensive review of potential risk factors for infections and therapeutic approaches for the most prevalent infections in patients with solid tumors, and discusses the potential effect of antibiotic therapy on toxicity and efficacy of cancer therapy.

show abstract

Urinary Tract Infection in Cancer Patients at Government Cancer Hospital Aurangabad, India

Cited by 5 publications

References 5 publications

Bacterial Profile and Antibiotic Resistance among Cancer Patients with Urinary Tract Infection in a National Tertiary Cancer Hospital of Nepal

Bacterial Profile and Antibiotic Resistance among Cancer Patients with Urinary Tract Infection in a National Tertiary Cancer Hospital of Nepal

Multiple Drug Resistance Patterns in Various Phylogenetic Groups of Hospital-Acquired Uropathogenic E. coli Isolated from Cancer Patients

Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors

Contact Info

Product

Resources

About